PXI Auto Components
301560
Shenzhen Crastal Technology
300824
Shenzhen Zesum Technology
301486
4
Hanjia Design Group
300746
5
Harbin Jiuzhou Group
300040
CN Stock MarketDetailed Quotes
300813 TAILIN
- 17.36
- +0.25+1.46%
Market Closed Apr 25 15:00 CST
2.10BMarket Cap217.00P/E (TTM)
17.90High17.22Low26.53KlotVolume17.71Open17.11Pre Close46.38MTurnover3.49%Turnover Ratio107.16P/E (Static)121.20MShares29.8052wk High3.22P/B1.32BFloat Cap14.1352wk Low20.53Limit Up76.05MShs Float66.50Historical High13.69Limit Down3.97%Amplitude10.78Historical Low0.10Dividend TTM17.49Avg Price13.13KlotAsk0.58%Div YieldTTM100Lot Size12.83KlotBid
TAILIN News
TAILIN (300813.SZ) established a wholly-owned subsidiary TAILIN New Materials.
TAILIN (300813.SZ) announced that, based on the needs of the company's Global Strategy development, the company has invested 10 million with its own funds...
Tailin Bioengineering to Buy Back Up to 40 Million Yuan Worth of Shares
TAILIN (300813.SZ): plans to propose an employee stock ownership plan in 2025.
On March 11, Gelonghui reported that TAILIN (300813.SZ) announced the employee stock ownership plan for 2025. This employee stock ownership plan will be obtained and held through non-trade transfer and other legal methods as approved by the company's shareholders' meeting. The total number of shares will not exceed 1.208 million shares, accounting for 1.00% of the company's current total share capital, with the specific number of shares determined based on the actual funding situation. After the shareholders' meeting approval, this employee stock ownership plan will acquire and hold the symbol Stocks through non-trade transfers and other legally permitted methods. This ownership plan will transfer the symbol.
TAILIN (300813.SZ): plans to repurchase shares for 20 million yuan to -40 million yuan.
Gelonghui, on March 11, announced that TAILIN (300813.SZ) plans to use a total of no less than 20 million yuan and no more than 40 million yuan for the repurchase of shares, with the specific total amount of funds for repurchase to be based on the actual amount used. Based on the repurchase cap of 40 million yuan and a maximum repurchase price of 27.56 yuan per share, the number of shares intended for repurchase is approximately 1.451378 million shares, not exceeding 1.20% of the company's currently issued total share capital; based on the minimum total amount of 20 million yuan and a maximum repurchase price of 27.56 yuan per share.
After on-site inspections of the sixth company this month, TAILIN and the Director received a warning letter | Quick read of the announcement.
① During the on-site inspection, issues such as insufficient production capacity for some public fundraising projects were discovered, resulting in TAILIN and related responsible persons receiving a warning letter from the Zhejiang Securities Regulatory Bureau; ② At the end of 2024, TAILIN had previously postponed the public fundraising project "Cell Therapy Industrial Equipment Manufacturing Base Project" by six months; ③ This is the sixth listed company warned after being inspected by the local Securities Regulatory Bureau this month.
TAILIN (300813.SZ) received a warning letter from the Zhejiang Securities Regulatory Bureau.
TAILIN Bio (300813.SZ) announced that the company recently received a notice from the Zhejiang Securities Regulatory Bureau regarding Zhejiang TAILIN...
TAILIN (300813.SZ): Plans to postpone the "Cell Therapy Industrialization Equipment Manufacturing Base Project" until June 30, 2025.
Gelonghui, December 31丨TAILIN (300813.SZ) announced that the company will hold the fifth meeting of the fourth Board of Directors and the fifth meeting of the fourth Supervisory Board on December 31, 2024. The proposal concerning the extension of the fundraising for the issuance of Convertible Bonds to unspecified entities was reviewed and approved. Under the condition that the investment project主体, implementation location, investment purpose, and investment scale do not change, based on the current actual construction progress of the fundraising investment project, the fundraising for the Convertible Bonds will be allocated to the "Cell Therapy Industrialization Equipment Manufacturing Base Project" to reach the predetermined usable state.
Revenues Not Telling The Story For Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) After Shares Rise 26%
Beyond Lackluster Earnings: Potential Concerns For Zhejiang Tailin BioEngineeringLtd's (SZSE:300813) Shareholders
Tailin Biotech: Report for the third quarter of 2024
Tailin (300813.SZ): The net income in the first three quarters decreased by 46.91% year-on-year to 11.3147 million yuan.
On October 29, Gleam Health reported on Tailin (300813.SZ) in the third quarter of 2024. The company achieved revenue of 0.242 billion yuan in the first three quarters, a year-on-year increase of 19.37%; net income attributable to shareholders of the listed company was 11.3147 million yuan, a year-on-year decrease of 46.91%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 10.7105 million yuan, a year-on-year decrease of 36.75%; basic earnings per share was 0.1 yuan.
Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) CEO Da Lin Ye, the Company's Largest Shareholder Sees 17% Reduction in Holdings Value
Tailin (300813.SZ): Wholly-owned subsidiaries have obtained a total of 8 patent certificates.
Gelonghui, September 10th, Tailin Biotech (300813.SZ) announced that its wholly-owned subsidiaries Zhejiang Tailin Analytical Instrument Co., Ltd. (referred to as "Tailin Analytical Instrument"), Zhejiang Tailin Life Science Co., Ltd. (referred to as "Tailin Life Science"), and Zhejiang Tailin Medical Engineering Co., Ltd. (referred to as "Tailin Medical Engineering") have recently obtained 8 patent certificates (including 2 invention patents). The specific situation is as follows:
Tailin Biotech: 2024 Semi-Annual Report Summary
Tailin Biotech: 2024 Semi-Annual Report
Tailin (300813.SZ): The net income in the first half of the year was 6.5821 million yuan, a year-on-year decrease of 71.62%.
Tailin Bio (300813.SZ) announced its semi-annual report for 2024, with a total operating revenue of 0.156 billion yuan during the reporting period, a year-on-year growth of 9.68%; net income attributable to shareholders of the listed company was 6,582.1 million yuan, a year-on-year decrease of 71.62%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 6,090.4 million yuan, a year-on-year decrease of 69.99%; basic earnings per share is 0.06 yuan.
Tailin (300813.SZ) released its performance for the first half of the year, with a net income of 6.5821 million yuan, a decrease of 71.62%.
Tailin (300813.SZ) released its 2024 interim report, with revenue of 0.156 billion...
Tailin (300813.SZ) currently does not produce in vitro diagnostic reagents.
Tailin stated on the investor interaction platform, that the current common detection methods for monkeypox virus are PCR amplification and immune detection. NC membrane can be used as the carrier of C/T line in immune chromatographic diagnostic reagents, and it is also the site of immune reaction, playing an important role in immune chromatographic technology as one of the key raw materials. The company's NC membrane series products can be used as production materials for diagnostic reagent kits based on lateral flow immune detection technology. However, the company currently does not produce in vitro diagnostic reagent kits, and there are no products available for direct detection.
Tailin (300813.SZ): Tailin's life science related products serve environmental monitoring, scientific research institutions, water conservancy, disease control and third-party testing institutions.
On July 26, Geelong News reported that Tailin's wholly-owned subsidiary, Life Science, is not only continuing to develop its microbiological testing business in the pharmaceutical industry, but also actively expanding its testing business in the water ecological field. The company is committed to becoming an excellent provider of water ecological (microorganisms + parasites + plankton) testing system solutions, and related products serve environmental monitoring, scientific research institutions, water conservancy and water affairs, disease control and third-party testing agencies. Tailin Life Science's layout in the water ecology field is also actively responding to the national call for ecological civilization construction.
Tailin (300813.SZ): The subsidiary has recently obtained 9 patent certificates and 1 software copyright certificate.
On July 22nd, Gelunhui reported that Tailin Biomedical (300813.SZ) announced that its wholly-owned subsidiary, Zhejiang Tailin Life Science Co., Ltd. (referred to as "Tailin Life Science") and Zhejiang Tailin Medical Instruments Co., Ltd. (referred to as "Tailin Medical Instruments") have jointly obtained nine patent certificates and one software copyright certificate recently. Situation of obtaining a patent certificate: Situation of obtaining a computer software copyright registration certificate: